- Animal-drug developer Dechra Pharmaceutical said revenues increased by about 17% amid another year of 'strong growth' driven by 'good' market penetration and the realisation of significant synergies from Le Vet.

For the financial year ended 30 June 2019, revenue increased by about 17%, with European Pharmaceuticals revenue growth up about 18% and North America Pharmaceuticals revenue growth up about 15%.

The integration of AST Farma/Le Vet, Caledonian and Venco, was proceeding well and trading was in line with expectations, the company said.

'We are pleased to have delivered another year of strong revenue growth. This has been driven from our core portfolio, good market penetration and realisation of significant Le Vet revenue synergies. In addition the newly acquired Caledonian and Venco businesses have performed well,' said Ian Page, Chief Executive Officer.

Story provided by